STOCK TITAN

CGEM (NASDAQ: CGEM) Form 144 shows 1,752-share proposed resale; insider sales listed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CGEM filing shows a proposed resale of 1,752 shares of common stock through Morgan Stanley Smith Barney LLC.

The filing lists multiple recent 10b5-1 sales by Jennifer Michaelson, including 8,000 shares sold on 02/20/2026 for $114,400.00 and 4,000 shares sold on 01/22/2026 for $49,200.00.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the CGEM Form 144 disclose?

The filing discloses a proposed resale of 1,752 shares of common stock through Morgan Stanley Smith Barney LLC. It also lists recent 10b5-1 sales by Jennifer Michaelson on specific dates with share counts and proceeds.

Who executed the recent sales reported in the filing for CGEM?

The filing lists multiple 10b5-1 sales executed by Jennifer Michaelson. Examples include 8,000 shares on 02/20/2026 and 4,000 shares on 01/22/2026, with stated proceeds.

How much proceeded from the 02/20/2026 sale in the CGEM filing?

The sale on 02/20/2026 of 8,000 shares shows proceeds of $114,400.00. The filing lists individual sale dates, share counts, and proceeds for several transactions.

Are these sales part of a trading plan for CGEM insiders?

Yes. The transactions are listed as 10b5-1 sales, indicating they were executed under an established trading plan. The filing enumerates dates, share counts, and proceeds for each reported sale.

Does the Form 144 list who is handling the resale for CGEM?

The resale is being processed through Morgan Stanley Smith Barney LLC, Executive Financial Services. The filing identifies the broker and provides the number of shares listed for resale (1,752 shares).
Cullinan Oncology Inc

NASDAQ:CGEM

CGEM Rankings

CGEM Latest News

CGEM Latest SEC Filings

CGEM Stock Data

826.48M
56.27M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
CAMBRIDGE